RE: 4-6 weeks now….25 Oct 2024 12:59
Doc.Daneeka: “what trial exactly would you like the Government to sponsor Bob ? Are you still interested in COPD ? Or prophylactic use ? Or further testing as a first use hospital drug ?”
You may have noticed that I have little clinical knowledge (other than my own visits to the Respiratory department). My background is business financial management. However, here is my response:
Using in-vitro testing, SNG001 has shown great promise as being a potential viral agnostic therapeutic. Being a potentially viral agnostic really opens the target market, hence the viability of different approaches. Longer term and making good use of recent assay development showing if an individual is deficient in IFN Beta, there may be a huge market as prophylactic (as mentioned by Sir Stephen at the 2023 AGM).
So, massive potential which I cleverly leave to my betters to develop. Cheers.
PMJH: In response to your point regarding finding the test population, would the Viral Agnostic potential not open a sufficiently large target hospitalised population? Also, working in conjunction with BARDA etc meets one of the strategic criteria and massively expends population opportunity. Cheers…and like so many others I always appreciate your contributions.